DexCom overview and recent share performance DexCom (DXCM) has drawn fresh attention as investors reassess its continuous glucose monitoring business and recent share performance, with the stock last ...

DexCom will likely make significant headway in its addressable market in the next five years. The company should also increase its reach by launching new products and entering new countries. Despite a ...

Now, it’s worth noting Stock Advisor’s total average return is 991 % — a market-crushing outperformance compared to 196% for ...

DexCom Inc. DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its ...

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM) (“Dexcom”) announced today the pricing of its offering of $1.1 billion aggregate principal amount of 0.375% Convertible Senior Notes due 2028 ...

DexCom, Inc.'s growth is impressive but limited by its niche market, with my projected ceiling being ~$7.5bn in peak annual revenues. Despite positive Q4 2024 results, DexCom's stock is fairly valued, ...

DexCom, Inc. (NASDAQ:DXCM) shareholders should be happy to see the share price up 12% in the last month. But that doesn't help the fact that the three year return is less impressive. In fact, the ...

Join the event trusted by enterprise leaders for nearly two decades. VB Transform brings together the people building real enterprise AI strategy. Learn more About one in three Americans, or 125 ...

DexCom, Inc. reduced its 2024 revenue guidance following a decline in new U.S. customers and revenue per customer, leading to a sharp share price drop, despite $750 million share buyback. DexCom faces ...

Medical device company DexCom (NASDAQ:DXCM) announced in Q3 CY2025, with sales up 21.6% year on year to $1.21 billion. The company expects the full year’s revenue to be around $4.64 billion, close to ...

The medical device maker has already made impressive gains. A planned stock split may make shares even more attractive to investors. DexCom's robust business performance is reflected in its surging ...

People with Type 1 diabetes are estimated to make up to 180 more decisions a day than someone without the disease, according to a study from Stanford University. Each meal, workout, or night’s sleep ...